La Jolla Pharmaceutical Company (LJPC) News
Filter LJPC News Items
LJPC News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest LJPC News From Around the Web
Below are the latest news stories about LA JOLLA PHARMACEUTICAL CO that investors may wish to consider to help them evaluate LJPC as an investment opportunity.
Biotech M&A returns as Vertex, Innoviva make buysCome, thou long-expected M&A. On Monday, Vertex Pharmaceuticals Inc. and Innoviva Inc. both announced that they were making acquisitions. Vertex (Nasdaq: VRTX) is set to buy ViaCyte, a cell therapy startup specializing in diabetes, for $320 million cash, while Innoviva will pay about $149 million for infectious diseases firm La Jolla Pharmaceutical Company (Nasdaq: LJPC). |
How this Peninsula company is turning lung drug royalties into acquisitionsWith the help of nearly $400 million in royalties from a well-known drug targeting asthma and COPD, the company wrapped up one acquisition and launched another. |
Innoviva Bolsters Its Infectious Disease, Hospital Portfolio With La Jolla DealInnoviva Inc (NASDAQ: INVA) has agreed to acquire La Jolla Pharmaceutical Company (NASDAQ: LJPC) for $5.95 per share, representing a premium of approximately 70% to the 30-day volume-weighted average price. Innoviva will also pay an incremental $0.28 per share for additional cash proceeds received in connection with the divestiture of a non-core asset. The deal consideration of $6.23 per share in cash has an implied enterprise value of approximately $149 million. The FDA approved La Jolla's lead |
Innoviva to Acquire La Jolla Pharmaceutical CompanyBURLINGAME, Calif. & WALTHAM, Mass., July 11, 2022--Innoviva, Inc. (Nasdaq: INVA), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, and La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced that they have entered into a definitive merger agreement whereby Innoviva will acquire |
La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2022 and Highlights Corporate ProgressWALTHAM, Mass., May 16, 2022--La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three months ended March 31, 2022 and highlighted corporate progress. |
AcelRx Pharmaceuticals (ACRX) Reports Q1 Loss, Lags Revenue EstimatesAcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 0% and 11.60%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock? |
Marinus Pharmaceuticals (MRNS) Reports Q1 Loss, Tops Revenue EstimatesMarinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 40.23% and 548.36%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock? |
Ardelyx (ARDX) Reports Q1 Loss, Tops Revenue EstimatesArdelyx (ARDX) delivered earnings and revenue surprises of -5% and 87.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock? |
The past five years for La Jolla Pharmaceutical (NASDAQ:LJPC) investors has not been profitableLong term investing works well, but it doesn't always work for each individual stock. We really hate to see fellow... |
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Twelve Months Ended December 31, 2021 and Highlights Corporate ProgressWALTHAM, Mass., March 09, 2022--La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three and twelve months ended December 31, 2021 and highlighted corporate progress. |